Bibliographic Details
| Title: |
High‐Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults. |
| Authors: |
Palmu, Arto A., Pepin, Stephanie, Syrjänen, Ritva K., Mari, Karine, Mallett Moore, Tamala, Jokinen, Jukka, Nieminen, Heta, Kilpi, Terhi, Samson, Sandrine I., De Bruijn, Iris |
| Source: |
Influenza & Other Respiratory Viruses; Apr2024, Vol. 18 Issue 4, p1-10, 10p |
| Subject Terms: |
FLU vaccine efficacy, INFLUENZA vaccines, OLDER people, HOSPITAL care, VACCINE effectiveness, STATISTICAL power analysis |
| Abstract: |
Background: We assessed the relative vaccine effectiveness (rVE) of high‐dose quadrivalent influenza vaccine (QIV‐HD) versus standard‐dose quadrivalent influenza vaccine (QIV‐SD) in preventing respiratory or cardiovascular hospitalizations in older adults. Methods: FinFluHD was a phase 3b/4 modified double‐blind, randomized pragmatic trial. Enrolment of 121,000 adults ≥65 years was planned over three influenza seasons (October to December 2019–2021). Participants received a single injection of QIV‐HD or QIV‐SD. The primary endpoint was first occurrence of an unscheduled acute respiratory or cardiovascular hospitalization (ICD‐10 primary discharge J/I codes), from ≥14 days post‐vaccination until May 31. The study was terminated after one season due to COVID‐19; follow‐up data for 2019–2020 are presented. Results: 33,093 participants were vaccinated (QIV‐HD, n = 16,549; QIV‐SD, n = 16,544); 529 respiratory or cardiovascular hospitalizations (QIV‐HD, n = 257; QIV‐SD, n = 272) were recorded. The rVE of QIV‐HD versus QIV‐SD to prevent respiratory/cardiovascular hospitalizations was 5.5% (95% CI, −12.4 to 20.7). When prevention of respiratory and cardiovascular hospitalizations were considered separately, rVE estimates of QIV‐HD versus QIV‐SD were 5.4% (95% CI, −28.0 to 30.1) and 7.1% (95% CI, −15.0 to 25.0), respectively. Serious adverse reactions were <0.01% in both groups. Conclusions: Despite insufficient statistical power due to the impact of COVID‐19, rVE point estimates demonstrated a trend toward a benefit of QIV‐HD over QIV‐SD. QIV‐HD was associated with lower respiratory or cardiovascular hospitalization rates than QIV‐SD, with a comparable safety profile. Adequately powered studies conducted over multiple influenza seasons are needed to determine statistical significance of QIV‐HD compared with QIV‐SD against preventing respiratory and cardiovascular hospitalizations. Trial Registration:ClinicalTrials.gov number: NCT04137887 [ABSTRACT FROM AUTHOR] |
|
Copyright of Influenza & Other Respiratory Viruses is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
